【摘要】 目的:探讨小剂量尿激酶和低分子肝素对急性进展性缺血性脑卒中的治疗作用。方法:将60例急性进展性脑卒中患者随机分成低分子肝素组30例,予低分子肝素0.4 ml,2次/d,皮下注射;尿激酶组30例,予尿激酶20~30万单位加生理盐水100 ml静滴,连用7 d;于治疗前、治疗7 d比较两组神经功能缺损评分。结果:低分子肝素组治疗总有效率90.0%,尿激酶组83.3%,二者比较差异无统计学意义(P>0.05),但尿激酶组出血副作用较大。结论:低分子肝素治疗急性进展性脑卒中较小剂量尿激酶的疗效可靠,相对安全。更多还原

【Abstract】 Objective:To investigate the effect of low-dose urokinase and low-molecular-weight heparin on acute progressive ischemic stroke.Methods: 60 patients with acute progressive ischemic stroke were randomly divided into two groups.30 patients received 0.4 ml of low-molecular-weight heparin by hypodermic injection two times a day;30 patients received low-dose urokinase 200 000～300 000 u addition to 100 ml normal saline by intravenous drip.Two groups were all used for 7 days.Compared before treatment with 7 days treatment later.Neurological deficits score were used.Results:The total effective rate of low-molecular weight heparin was 90.0%,and low dose urokinase was 83.3%,there was no difference between two groups(P>0.05).But urokinase had the heavy hemrrohage side effect.Conclusion:The therapeutic effect of low-molecular-weight heparin on acute progressive ischemic stroke was more progressive and safe than low-dose urokinase.更多还原